Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma.
Bagratuni T, Terpos E, Eleutherakis-Papaiakovou E, Kalapanida D, Gavriatopoulou M, Migkou M, Liacos CI, Tasidou A, Matsouka C, Mparmparousi D, Dimopoulos MA, Kastritis E. Bagratuni T, et al. Among authors: mparmparousi d. Br J Haematol. 2016 Jan;172(1):44-7. doi: 10.1111/bjh.13786. Epub 2015 Nov 13. Br J Haematol. 2016. PMID: 26564000 Free article.
Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Eleutherakis-Papaiakovou E, Migkou M, Matsouka C, Mparmparousi D, Gika D, Kafantari E, Ziogas D, Fotiou D, Panagiotidis I, Terpos E, Kastritis E. Dimopoulos MA, et al. Among authors: mparmparousi d. Am J Hematol. 2016 May;91(5):499-502. doi: 10.1002/ajh.24335. Epub 2016 Apr 4. Am J Hematol. 2016. PMID: 26890495 Free article. Clinical Trial.
Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma.
Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Migkou M, Gika D, Fotiou D, Kanellias N, Ziogas DC, Ntanasis-Stathopoulos I, Mparmparousi D, Gatou A, Katopi D, Manios E, Liontos M, Giannouli S, Tsirigotis P, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: mparmparousi d. Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):445-452. doi: 10.1016/j.clml.2019.10.014. Epub 2020 Feb 4. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32284296
Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.
Dimou M, Papageorgiou SG, Stavroyianni N, Katodritou E, Tsirogianni M, Kalpadakis C, Banti A, Arapaki M, Iliakis T, Bouzani M, Verrou E, Spanoudakis E, Giannouli S, Marinakis T, Mandala E, Mparmparousi D, Sachanas S, Dalekou-Tsolakou M, Hatzimichael E, Vadikolia C, Violaki V, Poziopoulos C, Tsirkinidis P, Chatzileontiadou S, Vervessou E, Ximeri M, Sioni A, Konstantinidou P, Kyrtsonis MC, Siakantaris MP, Angelopoulou MK, Pappa V, Konstantopoulos K, Panayiotidis P, Vassilakopoulos TP. Dimou M, et al. Among authors: mparmparousi d. Hematol Oncol. 2021 Aug;39(3):336-348. doi: 10.1002/hon.2842. Epub 2021 Mar 2. Hematol Oncol. 2021. PMID: 33583077
The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Papageorgiou SG, Kontos CK, Kotsianidis I, Vasilatou D, Symeonidis A, Galanopoulos A, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Diamantopoulos MA, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V. Papageorgiou SG, et al. Among authors: mparmparousi d. Hematol Oncol. 2018 Oct;36(4):693-700. doi: 10.1002/hon.2551. Epub 2018 Sep 7. Hematol Oncol. 2018. PMID: 30129144
The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
Papageorgiou SG, Vasilatou D, Kontos CK, Kotsianidis I, Symeonidis A, Galanopoulos AG, Hatzimichael E, Megalakaki A, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Mparmparousi D, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V. Papageorgiou SG, et al. Among authors: mparmparousi d. Am J Hematol. 2018 Jul;93(7):895-901. doi: 10.1002/ajh.25111. Epub 2018 May 16. Am J Hematol. 2018. PMID: 29659040 Free article.
The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry.
Diamantopoulos P, Koumbi D, Kotsianidis I, Pappa V, Symeonidis A, Galanopoulos A, Zikos P, Papadaki HA, Panayiotidis P, Dimou M, Hatzimichael E, Vassilopoulos G, Delimpasis S, Mparmparousi D, Papageorgiou S, Variami E, Kyrtsonis MC, Megalakaki A, Kotsopoulou M, Repousis P, Adamopoulos I, Kontopidou F, Christoulas D, Kourakli A, Tsokanas D, Konstantinos Papoutselis M, Kyriakakis G, Viniou NA; Hellenic MDS study group. Diamantopoulos P, et al. Among authors: mparmparousi d. Cancer Med. 2019 May;8(5):2056-2063. doi: 10.1002/cam4.2090. Epub 2019 Mar 21. Cancer Med. 2019. PMID: 30897290 Free PMC article.
Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes.
Papageorgiou SG, Kotsianidis I, Bouchla A, Symeonidis A, Galanopoulos A, Viniou NA, Hatzimichael E, Vassilakopoulos TP, Gogos D, Megalakaki A, Zikos P, Diamantopoulos P, Kourakli A, Giannoulia P, Papoutselis M, Poulakidas E, Arapaki M, Vardi A, Anagnostopoulos A, Mparmparousi D, Papaioannou M, Bouronikou E, Dimou M, Papadaki H, Panayiotidis P, Pappa V. Papageorgiou SG, et al. Among authors: mparmparousi d. Ther Adv Hematol. 2020 Dec 8;11:2040620720966121. doi: 10.1177/2040620720966121. eCollection 2020. Ther Adv Hematol. 2020. PMID: 33343854 Free PMC article.
Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Papageorgiou SG, Kontos CK, Kotsianidis I, Karousi P, Symeonidis A, Galanopoulos A, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V. Papageorgiou SG, et al. Among authors: mparmparousi d. J Geriatr Oncol. 2020 Jan;11(1):121-124. doi: 10.1016/j.jgo.2019.07.018. Epub 2019 Jul 27. J Geriatr Oncol. 2020. PMID: 31362867 No abstract available.
Visceral leishmaniasis and COVID-19 coinfection - A case report.
Pikoulas A, Piperaki ET, Spanakos G, Kallianos A, Mparmparousi D, Rentziou G, Trakada G. Pikoulas A, et al. Among authors: mparmparousi d. IDCases. 2022;27:e01358. doi: 10.1016/j.idcr.2021.e01358. Epub 2021 Dec 6. IDCases. 2022. PMID: 34900591 Free PMC article.
12 results